BNP Paribas Financial Markets’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

BNP Paribas Financial Markets’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-12,817	Closed	-$24K	–	4105
2022 Q4	$24K	Sell	12,817 -11,719	-48%	-$29.2K	﹤0.01%	3528
2022 Q3	$63.1K	Sell	24,536 -6,944	-22%	-$17.3K	﹤0.01%	3931
2022 Q2	$60.8K	Sell	31,480 -9,444	-23%	-$20.6K	﹤0.01%	3507
2022 Q1	$122K	Sell	40,924 -7,700	-16%	-$29K	﹤0.01%	3311
2021 Q4	$218K	Buy	48,624 +40,657	+510%	+$193K	﹤0.01%	3370
2021 Q3	$38.7K	Buy	7,967 +6,302	+378%	+$34.7K	﹤0.01%	3572
2021 Q2	$11.4K	Sell	1,665 -3,998	-71%	-$32.3K	﹤0.01%	3692
2021 Q1	$40K	Sell	5,663 -2,260	-29%	-$16.3K	﹤0.01%	3656
2020 Q4	$49.6K	Sell	7,923 -1,384	-15%	-$8.14K	﹤0.01%	3555
2020 Q3	$50.4K	Buy	9,307 +7,222	+346%	+$35.8K	﹤0.01%	3468
2020 Q2	$10.9K	Sell	2,085 -8,079	-79%	-$35.9K	﹤0.01%	3668
2020 Q1	$32K	Buy	10,164 +5,570	+121%	+$20.5K	﹤0.01%	3753
2019 Q4	$18.5K	Sell	4,594 -566	-11%	-$1.96K	﹤0.01%	4022
2019 Q3	$22.3K	Buy	5,160 +1,584	+44%	+$6.33K	﹤0.01%	3900
2019 Q2	$14.3K	Sell	3,576 -3,105	-46%	-$14.8K	﹤0.01%	4013
2019 Q1	$35.8K	Buy	+6,681	New	+$43.1K	﹤0.01%	3689
2018 Q4	–	Sell	-1,002	Closed	-$9.72K	–	4466
2018 Q3	$9.72K	Hold	1,002	–	–	﹤0.01%	3746
2018 Q2	$10.2K	Sell	1,002 -4,491	-82%	-$50.8K	﹤0.01%	3773
2018 Q1	$71.4K	Buy	5,493 +489	+10%	+$7.28K	﹤0.01%	3364
2017 Q4	$89.6K	Buy	5,004 +2,618	+110%	+$54.6K	﹤0.01%	3362
2017 Q3	$59.9K	Sell	2,386 -145	-6%	-$3.38K	﹤0.01%	3053
2017 Q2	$61K	Buy	2,531 +2,453	+3,145%	+$54.2K	﹤0.01%	3083
2017 Q1	$1.5K	Sell	78 -943	-92%	-$14.9K	﹤0.01%	3611
2016 Q4	$15.7K	Sell	1,021 -276	-21%	-$3.58K	﹤0.01%	3275
2016 Q3	$16.9K	Buy	1,297 +734	+130%	+$9.73K	﹤0.01%	2981
2016 Q2	$7.83K	Buy	+563	New	+$8.29K	﹤0.01%	3039
2016 Q1	–	Sell	-2,390	Closed	-$45.3K	–	3172
2015 Q4	$45.3K	Sell	2,390 -29	-1%	-$554	﹤0.01%	2874
2015 Q3	$46K	Buy	2,419 +1,404	+138%	+$35K	﹤0.01%	2928
2015 Q2	$26.2K	Buy	+1,015	New	+$28.8K	﹤0.01%	2875
2014 Q3	–	Sell	-95	Closed	-$2.27K	–	4324
2014 Q2	$2.27K	Hold	95	–	–	﹤0.01%	3029
2014 Q1	$3.37K	Hold	95	–	–	﹤0.01%	2516
2013 Q4	$3.84K	Buy	+95	New	+$4.03K	﹤0.01%	3280

Other funds holding PRTK

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

NAM

Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

GAI

General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.82% 1-Year Est. Return

BNP Paribas Financial Markets's PRTK Position: Q1 2023 in Review

BNP Paribas Financial Markets sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q1 2023, closing a stake of 12,817 shares — an estimated $24K sold.

BNP Paribas Financial Markets first reported a position in PRTK in Q4 2013 and held it in 32 quarters. The position peaked at $218K in Q4 2021. 63 funds tracked by Wall St. Rank hold PRTK as of Q1 2023.

BNP Paribas Financial Markets reported no remaining Paratek Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
BNP Paribas Financial Markets sold 12,817 Paratek Pharmaceuticals, Inc. shares in Q1 2023, an estimated $24K.
BNP Paribas Financial Markets first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2013 and held it in 32 quarters.
BNP Paribas Financial Markets's Paratek Pharmaceuticals, Inc. position peaked at $218K in Q4 2021.
63 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q1 2023.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2023, filed 12 May 2023.